Japan
· Delayed Price · Currency is JPY Fuji Pharma Statistics
Total Valuation
Fuji Pharma has a market cap or net worth of JPY 32.32 billion. The enterprise value is 58.00 billion.
| Market Cap | 32.32B |
| Enterprise Value | 58.00B |
Important Dates
The next estimated earnings date is Thursday, August 7, 2025.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | Sep 29, 2025 |
Share Statistics
Fuji Pharma has 24.43 million shares outstanding. The number of shares has increased by 0.15% in one year.
| Current Share Class | 24.43M |
| Shares Outstanding | 24.43M |
| Shares Change (YoY) | +0.15% |
| Shares Change (QoQ) | +0.38% |
| Owned by Insiders (%) | 41.41% |
| Owned by Institutions (%) | 13.05% |
| Float | 12.33M |
Valuation Ratios
The trailing PE ratio is 10.14 and the forward PE ratio is 8.96.
| PE Ratio | 10.14 |
| Forward PE | 8.96 |
| PS Ratio | 0.66 |
| PB Ratio | 0.71 |
| P/TBV Ratio | 0.96 |
| P/FCF Ratio | 6.25 |
| P/OCF Ratio | 4.80 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.67, with an EV/FCF ratio of 11.22.
| EV / Earnings | 18.26 |
| EV / Sales | 1.19 |
| EV / EBITDA | 6.67 |
| EV / EBIT | 12.23 |
| EV / FCF | 11.22 |
Financial Position
The company has a current ratio of 1.57, with a Debt / Equity ratio of 0.71.
| Current Ratio | 1.57 |
| Quick Ratio | 0.79 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | 3.72 |
| Debt / FCF | 6.26 |
| Interest Coverage | 18.60 |
Financial Efficiency
Return on equity (ROE) is 7.07% and return on invested capital (ROIC) is 3.97%.
| Return on Equity (ROE) | 7.07% |
| Return on Assets (ROA) | 3.34% |
| Return on Invested Capital (ROIC) | 3.97% |
| Return on Capital Employed (ROCE) | 7.59% |
| Revenue Per Employee | 29.46M |
| Profits Per Employee | 1.92M |
| Employee Count | 1,658 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 1.35 |
Taxes
In the past 12 months, Fuji Pharma has paid 822.00 million in taxes.
| Income Tax | 822.00M |
| Effective Tax Rate | 20.56% |
Stock Price Statistics
The stock price has decreased by -7.74% in the last 52 weeks. The beta is 0.27, so Fuji Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.27 |
| 52-Week Price Change | -7.74% |
| 50-Day Moving Average | 1,303.74 |
| 200-Day Moving Average | 1,374.92 |
| Relative Strength Index (RSI) | 56.91 |
| Average Volume (20 Days) | 41,095 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Fuji Pharma had revenue of JPY 48.85 billion and earned 3.18 billion in profits. Earnings per share was 130.48.
| Revenue | 48.85B |
| Gross Profit | 19.50B |
| Operating Income | 4.74B |
| Pretax Income | 4.00B |
| Net Income | 3.18B |
| EBITDA | 8.70B |
| EBIT | 4.74B |
| Earnings Per Share (EPS) | 130.48 |
Balance Sheet
The company has 6.70 billion in cash and 32.37 billion in debt, giving a net cash position of -25.68 billion or -1,051.06 per share.
| Cash & Cash Equivalents | 6.70B |
| Total Debt | 32.37B |
| Net Cash | -25.68B |
| Net Cash Per Share | -1,051.06 |
| Equity (Book Value) | 45.73B |
| Book Value Per Share | 1,872.05 |
| Working Capital | 17.35B |
Cash Flow
In the last 12 months, operating cash flow was 6.73 billion and capital expenditures -1.56 billion, giving a free cash flow of 5.17 billion.
| Operating Cash Flow | 6.73B |
| Capital Expenditures | -1.56B |
| Free Cash Flow | 5.17B |
| FCF Per Share | 211.56 |
Margins
Gross margin is 39.92%, with operating and profit margins of 9.71% and 6.50%.
| Gross Margin | 39.92% |
| Operating Margin | 9.71% |
| Pretax Margin | 8.19% |
| Profit Margin | 6.50% |
| EBITDA Margin | 17.81% |
| EBIT Margin | 9.71% |
| FCF Margin | 10.58% |
Dividends & Yields
This stock pays an annual dividend of 45.50, which amounts to a dividend yield of 3.44%.
| Dividend Per Share | 45.50 |
| Dividend Yield | 3.44% |
| Dividend Growth (YoY) | 7.06% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 34.23% |
| Buyback Yield | -0.15% |
| Shareholder Yield | 3.31% |
| Earnings Yield | 9.83% |
| FCF Yield | 15.99% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 27, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Jun 27, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Fuji Pharma has an Altman Z-Score of 1.89 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.89 |
| Piotroski F-Score | 7 |